Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hologic’s Tomosynthesis Improves Cancer Detection Rates Of Mammography In Study

This article was originally published in The Gray Sheet

Executive Summary

3D breast tomosynthesis improves the recall rate and cancer-detection rate of mammography, according to a retrospective study of 454,850 examinations. The results may be good news for Hologic, which has struggled to accelerate adoption for the technology due to lack of reimbursement.

You may also be interested in...

Evidence Lacking To Assess Added Dense-Breast, 3-D Mammo Cancer Screens, Task Force Says

In a draft recommendation, the U.S. Preventive Services Task Force says evidence is "insufficient" to assess 3D tomosynthesis for breast cancer screening, as well as for additional dense-breast screening by any modality.

CMS Sets Higher Reimbursement Rates For 3D Mammography

Hologic has struggled to gain market acceptance of its 3D breast tomosynthesis technologies because of the lack of reimbursement. But CMS has now delivered a long-awaited surplus rate for 3D compared to 2D scans, which is expected to boost adoption.

FDA Approves GE’s 3D Tomosynthesis Breast Imager

GE Healthcare’sSenoClaire breast tomosynthesis system will go head-to-head with Hologic’s 3D mammography system.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts